140 related articles for article (PubMed ID: 3193189)
21. Flow cytometric determination of modal DNA population in relation to proliferative potential of human intracranial neoplasms.
Cho KG; Nagashima T; Barnwell S; Hoshino T
J Neurosurg; 1988 Oct; 69(4):588-92. PubMed ID: 3418392
[TBL] [Abstract][Full Text] [Related]
22. S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine.
Hoshino T; Nagashima T; Cho KG; Murovic JA; Hodes JE; Wilson CB; Edwards MS; Pitts LH
Int J Cancer; 1986 Sep; 38(3):369-74. PubMed ID: 3527993
[TBL] [Abstract][Full Text] [Related]
23. The prognostic implications of histologic classification and bromodeoxyuridine labeling index of mixed gliomas.
Wacker MR; Hoshino T; Ahn DK; Davis RL; Prados MD
J Neurooncol; 1994; 19(2):113-22. PubMed ID: 7964986
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of 201Tl SPECT in patients with glioma: a comparative study with histological diagnosis, clinical feature and proliferative activity].
Oriuchi N; Tamura M; Shibazaki T; Inoue T; Watanabe N; Tateno M; Tomiyoshi K; Hirano T; Igarashi H; Endo K
Kaku Igaku; 1991 Nov; 28(11):1263-71. PubMed ID: 1770641
[TBL] [Abstract][Full Text] [Related]
25. A comparison of CT contrast enhancement and BUDR labeling indices in moderately and highly anaplastic astrocytomas of the cerebral hemispheres.
McDermott MW; Krouwer HG; Asai A; Ito S; Hoshino T; Prados MD
Can J Neurol Sci; 1992 Feb; 19(1):34-9. PubMed ID: 1562905
[TBL] [Abstract][Full Text] [Related]
26. [A review of cell kinetic studies on brain tumors with special reference to anti-bromodeoxyuridine monoclonal antibody method].
Nagashima T; Hoshino T
No Shinkei Geka; 1984 Aug; 12(9):1007-18. PubMed ID: 6390240
[TBL] [Abstract][Full Text] [Related]
27. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma.
Mizumatsu S; Tamiya T; Ono Y; Abe T; Matsumoto K; Furuta T; Ohmoto T
Clin Cancer Res; 1999 Mar; 5(3):551-7. PubMed ID: 10100706
[TBL] [Abstract][Full Text] [Related]
28. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
29. Cell kinetics studies of human brain tumors by in vitro labeling using anti-BUdR monoclonal antibody.
Nishizaki T; Orita T; Saiki M; Furutani Y; Aoki H
J Neurosurg; 1988 Sep; 69(3):371-4. PubMed ID: 3404235
[TBL] [Abstract][Full Text] [Related]
30. Changes of the bromodeoxyuridine labeling index of astrocytic tumors between primary and recurrent lesions.
Tamura M; Ono N; Zama A; Kurihara H
Noshuyo Byori; 1994; 11(2):173-6. PubMed ID: 7894621
[TBL] [Abstract][Full Text] [Related]
31. Gemistocytic astrocytomas: a reappraisal.
Krouwer HG; Davis RL; Silver P; Prados M
J Neurosurg; 1991 Mar; 74(3):399-406. PubMed ID: 1993905
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults.
Chaichana KL; Kosztowski T; Niranjan A; Olivi A; Weingart JD; Laterra J; Brem H; Quiñones-Hinojosa A
J Neurosurg; 2010 Aug; 113(2):286-92. PubMed ID: 20302391
[TBL] [Abstract][Full Text] [Related]
33. Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas.
Maris C; Rorive S; Sandras F; D'Haene N; Sadeghi N; Bièche I; Vidaud M; Decaestecker C; Salmon I
Neuropathol Appl Neurobiol; 2008 Jun; 34(3):316-29. PubMed ID: 17983425
[TBL] [Abstract][Full Text] [Related]
34. Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas.
Thotakura M; Tirumalasetti N; Krishna R
J Cancer Res Ther; 2014; 10(3):641-5. PubMed ID: 25313753
[TBL] [Abstract][Full Text] [Related]
35. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas.
Colman H; Giannini C; Huang L; Gonzalez J; Hess K; Bruner J; Fuller G; Langford L; Pelloski C; Aaron J; Burger P; Aldape K
Am J Surg Pathol; 2006 May; 30(5):657-64. PubMed ID: 16699322
[TBL] [Abstract][Full Text] [Related]
36. Cell kinetics of rat 9L brain tumors determined by double labeling with iodo- and bromodeoxyuridine.
Asai A; Shibui S; Barker M; Vanderlaan M; Gray JW; Hoshino T
J Neurosurg; 1990 Aug; 73(2):254-8. PubMed ID: 2366082
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
[TBL] [Abstract][Full Text] [Related]
38. Low-grade astrocytomas: the prognostic value of fibrillary, gemistocytic, and protoplasmic tumor histology.
Babu R; Bagley JH; Park JG; Friedman AH; Adamson C
J Neurosurg; 2013 Aug; 119(2):434-41. PubMed ID: 23662821
[TBL] [Abstract][Full Text] [Related]
39. Cell kinetics of glial tumors.
Hoshino T
Rev Neurol (Paris); 1992; 148(6-7):396-401. PubMed ID: 1448658
[TBL] [Abstract][Full Text] [Related]
40. Comparison of three quantitation methods for PCNA immunostaining: applicability and relation to survival in 83 astrocytic neoplasms.
Haapasalo HK; Sallinen PK; Helén PT; Rantala IS; Helin HJ; Isola JJ
J Pathol; 1993 Nov; 171(3):207-14. PubMed ID: 7903983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
